Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$476.49 - $1,165.85
Previous CloseN/A
Volume208.99K
Average Volume (3M)981.82K
Market Cap
$60.69B
Enterprise Value$52.23B
Total Cash (Recent Filing)$7.47B
Total Debt (Recent Filing)$2.71B
Price to Earnings (P/E)14.4
Beta0.74
Next Earnings
Oct 30, 2025EPS Estimate
9.67Last Dividend Ex-Date
Aug 18, 2025Dividend Yield0.45%
Share Statistics
EPS (TTM)12.89
Shares Outstanding104,170,296
10 Day Avg. Volume968,955
30 Day Avg. Volume981,816
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda9.63
Forecast
1Y Price Target
$739.95Price Target Upside26.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Bulls Say, Bears Say
Bulls Say
Oncology FranchiseAnalyst's recommendation of an Outperform rating on REGN shares is supported by a positive view of the oncology franchise and cautious optimism for the earlier-stage pipeline.
Product LaunchThe Sandoz aflibercept biosimilar launch agreement reads as an incremental positive for Regeneron shares, notably delaying launch of the product to 4Q26.
Research And DevelopmentRegeneron’s ability to translate R&D spend to EV growth should not be underestimated, as this productivity is the basis for long-term success in biotech.
Bears Say
Clinical Trial ResultsThe combination treatment of cemdisiran with pozelimab was less efficacious than cemdisiran alone in improving symptoms of generalized myasthenia gravis.
Commercialization StrategyCommercialization story remains uncertain as there is a need to hear more about a potential commercial strategy for Regeneron to penetrate the allergy market.
Trial EfficacyThe efficacy results of the trial fall short compared to competitors' treatments for generalized myasthenia gravis.
Regeneron News
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $476.49 and its highest was $1165.85 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $60.69B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Oct 30, 2025 which is in 42 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Aug 07, 2025. The company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.431 by $4.459.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Quarterly dividend of $0.88 which represents an annual dividend yield of 0.45%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 9.67.
How many shares outstanding does Regeneron have?
Regeneron has 104,170,296 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $12.89 in its last earnings report, beating expectations of $8.431. Following the earnings report the stock price went up 0.841%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
Regeneron Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$739.95 (26.38% Upside)
$739.95 (26.38% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.91%
12-Months-Change
Fundamentals
Return on Equity
15.34%
Trailing 12-Months
Asset Growth
5.91%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
REGN Company Deck
REGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Regeneron showed strong performance in key products like Dupixent and Libtayo, successful launches, and robust financial results, offsetting the declines in EYLEA sales and regulatory delays. The company's significant R&D investments indicate a focus on future growth, despite facing competitive pressures and market dynamics.View all REGN earnings summariesREGN Revenue Breakdown
53.72% Net product sales
42.65% Collaboration revenue
3.63% Other
REGN Stock 12 Month Forecast
Average Price Target
$739.95
▲(26.38% Upside)
Technical Analysis
Ownership Overview
0.26% Insiders
27.85% Mutual Funds
21.06% Other Institutional Investors
23.45% Public Companies and Individual Investors